Brigham and Women's Hospital, Spotlight Innovation partner to support Dr. Kevin Hodgetts' spinal muscular atrophy research: 5 things to know

Written by Megan Wood | June 30, 2017 | Print  |

Spotlight Innovation and Boston-based Brigham and Women's Hospital entered into a sponsored research agreement to develop drugs for spinal muscular atrophy treatment.

Here are five things to know:


1. The agreement will support the research of Kevin Hodgetts, PhD.


2. Dr. Hodgetts' research will focus on developing safe and effective drugs for SMA treatment.


3. Dr. Hodgetts serves on Spotlight Innovation's scientific advisory board, and co-invented STL-182, Spotlight Innovation's product for SMA treatment.


4. He heads medicinal chemistry and serves as director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital. Dr. Hodgetts is also an assistant professor of neurology at Boston-based Harvard Medical School.


5. Equipped with more than 15 years of experience in central nervous system disease treatment, Dr. Hodgetts founded and co-chairs Klogene Therapeutics' scientific advisory board.

More articles on spine:
Can patient-reported outcomes predict patient satisfaction for cervical spine surgery? 5 key notes
What personal habits do spine surgeons employ to take care of their own health?
The essential traits of successful spine surgeon leaders

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months